TERT and hepatocellular carcinoma: Recently, activating mutations have been identified by whole genome sequencing analysis at 124 bp (mostly G > A and rarely G > T) and 146 bp (G > A) before the ATG start site in the promoter region of TERT gene in several human tumors including melanoma, glioblastoma, bladder cancer, anaplastic thyroid cancer and HCC [34–37].